Background: Plasmablastic lymphoma (PL) is a relatively new category of lymphoma, which has been considered to be found predominantly in the oral cavity and has a strong association with HIV. Case: We report a case of extraoral/mesenteric PL detected using cytological examination of ascitic fluid assisted by flow cytometric (FC) analysis. The cells were positive for CD38, CD138, CD10, CD45 and CD56 and negative for CD3, CD19, CD20 and CD79a, with cytoplasmic lambda light-chain restriction. We also reviewed 67 cases of extraoral PL from the available literature and found them to be less often associated with HIV (than oral PL), occurring mostly in males aged 30-60 years, with the most common extraoral site being the anorectal region. Conclusion: A high index of suspicion at the level of the cytopathologist is imperative for identifying lymphoma cells in a body fluid. A rare entity like PL can also be diagnosed on cytology assisted by ancillary techniques (like FC), without the need for a biopsy. We also suggest that the minimum panel to diagnose PLs should include CD138, MUM-1, Ki-67, ALK-1, CD3, immunoglobulin light-chains, CD20 and PAX5.

Keywords:
Plasmablastic lymphoma, Cytology, Flow cytometry, Ascites
1.
Das DK: Serous effusions in malignant lymphomas: a review. Diagn Cytopathol 2006;34:335-347.
2.
Tong LC, Ko HM, Saieg MA, Boerner S, et al: Subclassification of lymphoproliferative disorders in serous effusions. Cancer Cytopathol 2013;121:261-270.
3.
Czader M, Ali SZ: Flow cytometry as an adjunct to cytomorphologic analysis of serous effusion. Diagn Cytopathol 2003;29:74-78.
4.
Zeppa P, Vigliar E, Cozzolino I, Troncone G, et al: Fine needle aspiration cytology and flow cytometry immunophenotyping of non-Hodgkin lymphoma: can we do better? Cytopathology 2010;21:300-310.
5.
Delecluse HJ, Anagnostopoulos F, Dallenbach F, Hummel M, et al: Plasmablastic lymphoma of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-1420.
6.
Tavora F, Gonzalez-Cuyar LF, Sun CJ, Burke A, et al: Extra-oral plasmablastic lymphoma: report of a case and review of literature. Hum Pathol 2006;37:1233-1236.
7.
Sarode SC, Sarode GS, Patil A: Plasmablastic lymphoma of the oral cavity: a review. Oral Oncol 2010;46:146-153.
8.
Gatter KC, Warnke RA: Diffuse large B cell lymphoma; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): Tumors of Hematopietic and Lymphoid Tissue, ed 3. Lyon, IARC Press, 2001, pp 173-174.
9.
Stein H, Harris NL, Campo E: Plasmablastic lymphoma; in Swerdlow SH, Campo E, Harros NL, Jaffe ES, et al (eds): WHO Classification of Tumors of Hematopietic and Lymphoid Tissue, ed 4. Lyon, IARC Press, 2008, pp 256-257.
10.
Lin F, Zhang K, Quiery AT, Prichard J, et al: Plasmablastic lymphoma of the cervical lymph nodes in a human immunodeficiency virus-negative patient: a case report and review of the literature. Arch Pathol Lab Med 2004;128:581-584.
11.
Hansra D, Montague N, Stefanovic A, Akunyili I, et al: Oral and extraoral plasmablastic lymphoma. Am J Clin Pathol 2010;134:710-719.
12.
Thakral C, Thomas L, Gajra A, Hutchison RE, et al: Plasmablastic lymphoma in an immunocompetent patient. J Clin Oncol 2009;27:e78-e81.
13.
Plaza R, Ponferrada A, Benito DM, Arevalo N, et al: Plasmablastic lymphoma associated with Crohn's disease and hepatitis C virus chronic infection. J Crohn's Colitis 2011;5:628-632.
14.
Van Vrancken MJ, Keglovits L, Krause J. Plasmablastic lymphoma following transplantation. Proc (Bayl Univ Med Cent) 2013;26:152-155.
15.
Mihaljevic BS, Todorovic DR, Andjelic BM, Antic D, et al: Unusual presentation of gastric plasmablastic lymphoma in a HIV-negative patient. Med Oncol 2012;29:1186.
16.
Vega F, Chang C, Medeiros LJ, Udden MM, Cho-Vega JH, et al: Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 2005;18:806-815.
17.
Teruya-Feldstein J, Chiao E, Filippa DA, Lin O, et al: CD20-negative large cell lymphoma with plasmablastic features: a clinically heterogeneous spectrum in both HIV-positive and negative patients. Ann Oncol 2004;15:1673-1679.
18.
Tille J, Pelte M, Schwartz J, Dietrich P, et al: Plasmablastic lymphoma clinically presenting in the urinary tract. Ann Diagn Pathol 2012;16:219-223.
19.
Mani D, Guinee DG Jr, Aboulafia DM: AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: a diagnostic dilemma. World J Gastroenterol 2008;14:4395-4399.
20.
Brahmania M, Sylwesterowic T, Leitch H: Plasmablastic lymphoma in the ano-rectal junction presenting in an immunocompetent man: a case report. J Med Case Rep 2011;5:168.
21.
Lopez-Iniguez A, Llamas-Covarrubias MA, Navarro-Blackaller G, Velez-Gomer E, et al: World J Oncol 2013;4:54-57.
22.
Chetty R, Hlatswayo N, Muc R, Sabaratnam R, Gatter K: Plasmablastic lymphoma in HIV+ patients: an expanding spectrum. Histopathology 2003;42:605-609.
23.
Rajagopal AS, Copson E, Addis B, Shinkfield M, et al: Plasmablastic lymphoma: a case of rectal disease with spinal cord compression. Leuk Lymphoma 2006;47:2670-2673.
24.
Chapman-Fredricks J, Montague N, Akunyili I, Ikpatt O: Extraoral plasmablastic lymphoma with intravascular component and MYC translocation. Ann Diagn Pathol 2012;16:48-53.
25.
Pruneri G, Graziadei G, Ermellino L, Baldini L: Plasmablastic lymphoma of the stomach. A case report. Hematologica 1998;83:87-89.
26.
Khurana A, Jalpota Y: Plasmablastic lymphoma in human immunodeficiency virus negative patient. Ind J Pathol Microbiol 2010;53:368-369.
27.
Lipstein M, O'Connor O, Montanari F, Paoluzzi L, et al: Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:E43-E46.
28.
Nicol I, Boye T, Carsuzaa F, Feier L, et al: Post-transplant plasmablastic lymphoma of the skin. Br J Dermatol 2003;149:889-891.
29.
Verma S, Nuovo GJ, Porcu P, Baiocchi RA, et al: Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation. J Cutan Pathol 2005;31:35-39.
30.
Hernandez C, Cetner AS, Wiley EL: Cutaneous presentation of plasmablastic post-transplant lymphoproliferative disorder in a 14-month old. Pediatr Dermatol 2009;26:713-716.
31.
Jambusaria A, Shafer D, Wu H, Al-Saleem T, Perlis C. J Am Acad Dermatol 2008;58:676-678.
32.
Mulay K, Ali MJ, Reddy VA, Honavar SG: Orbital plasmablastic lymphoma: a clinico-pathological correlation of a rare disease and review of literature. Clin Ophthalmol 2012;6:2049-2057.
33.
Kim JE, Kim YA, Kim WY, Kim CW, et al: Human immunodeficiency virus-negative plasmablastic lymphoma in Korea. Leuk Lymphoma 2009;50:582-587.
34.
Valenzuela AA, Walker NJ, Sullivan TJ: Plasmablastic lymphoma in the orbit: case report. Orbit 2008;27:227-229.
35.
Zhang LY, Lin HY, Gao LX, Li L, et al: Primary central nervous system plasmablastic lymphoma presenting in a human immunodeficiency virus-negative but Epstein-Barr virus-positive patient: a case report. Diagn Pathol 2012;7:51.
36.
Saraceni C, Agostino N, Cornfield DB, Gupta R: Plasmablastic lymphoma of the maxillary sinus in an HIV-negative patient: a case report and literature review. SpringerPlus 2013;2:142.
37.
Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, et al: Plasmablastic lymphoma with MYC translocation: evidence of a common pathway in the generation of plasmablastic features. Mod Pathol 2010;23:991-999.
38.
Lin Y, Rodriguez GD, Turner JF, Vasef MA, et al: Plasmablastic lymphoma of the lung. Arch Pathol Lab Med 2001;125:282-285.
39.
Masgala A, Christopoulos C, Giannakou N, Boukis H, et al: Plasmablastic lymphoma of the visceral cranium, cervix and thorax in an HIV-negative woman. Ann Hematol 2007;86:615-618.
40.
Cha JM, Lee JI, Joo KR, Jung SW, et al: A case report with plasmablastic lymphoma of the jejunum. J Korean Med Sci 2010;25:496-500.
41.
Kravetz JD, Rose MG, Payne-Blackman S, Federman DG: Plasmablastic lymphoma presenting as an arm mass in an individual negative for human immunodeficiency virus: a case report. Clin Lymphoma Myeloma 2006;6:493-495.
42.
Mondal SK, Bera H, Biswas PK, Mallick MG: High-grade plasmablastic neoplasm of humerus in an HIV-negative patient, which was indeterminate between plasmablastic lymphoma and plasmablastic myeloma. J Can Res Ther 2011;7:214-216.
43.
Chabay P, De Matteo P, Lorenzetti M, Gutierrez M, et al: Vulvar plasmablastic lymphoma in a HIV-positive child: a novel extra-oral localization. J Clin Pathol 2009;62:644-646.
44.
Ojanguren J, Collazos J, Martinez C, Alvarez J, et al: Epstein-Barr virus related plasmablastic lymphomas arising from long-standing sacrococcygeal cysts in immunosuppressed patients. AIDS 2003;17:1582-1584.
45.
Takahashi Y, Saiga I, Fukushima J, Seki N, et al: Plasmablastic lymphoma of the retroperitoneum in an HIV-negative patient. Pathol Int 2009;59:868-873.
46.
Nasta SD, Carrum GM, Shahab I, hanania NA, et al: Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma 2002;43:423-426.
47.
Redmond M, Quinn J, Murphy P, Patchett S, et al: Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn's disease after immunosuppressive therapy. J Clin Pathol 2007;60:80-81.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.